Skip to main content

Table 8 Membership details provided split by journal

From: A cohort examination to establish reporting of the remit and function of Trial Steering Committees in randomised controlled trials

   Journal (N reporting TSC) Total (N = 144)
BMJ (N = 6) NEJM (N = 34) Lancet (N = 20) HTA (N = 84)
Number of members n (n/N%) 3 (50.0) 20 (58.8) 16 (80.0) 71 (84.5) 110 (76.4)
mean (SD) 5 (2) 13 (12) 8 (5) 8 (6) 9 (7)
median (IQR) 5 (3) 9 (9) 6 (5) 6 (5) 7 (6)
(min, max) (4, 7) (4, 52) (3, 22) (2, 34) (2, 52)
Chair indicated n (n/N%) 3 (50.0) 20 (58.8) 9 (45.0) 52 (61.9) 84 (58.3)
Expertise of members indicated n (n/N %) 1 (16.7) 10 (29.4) 4 (20.0) 51 (60.7) 66 (45.8)
Expertise Chief investigator n (n/N%) 0 (0.0) 9 (26.5) 2 (10.0) 13 (15.5) 24 (16.7)
Trial coordinator n (n/N%) 0 (0.0) 1 (2.9) 0 (0.0) 5 (6.0) 6 (4.2)
Clinical expert n (n/N%) 0 (0.0) 3 (8.8) 2 (10.0) 41 (48.8) 46 (31.9)
Statistician n (n/N%) 0 (0.0) 4 (11.8) 2 (10.0) 23 (27.4) 29 (20.1)
PPI representative n (n/N%) 1 (16.7) 2 (5.9) 0 (0.0) 36 (42.9) 39 (27.1)
Health economist n (n/N%) 0 (0.0) 0 (0.0) 0 (0.0) 11 (13.1) 11 (7.6)
Sponsor representative n (n/N%) 0 (0.0) 5 (14.7) 1 (5.0) 2 (2.4) 8 (5.6)
Industry representative n (n/N%) 0 (0.0) 1 (2.9) 0 (0.0) 1 (1.2) 2 (1.4)
  1. BMJ British Medical Journal, HTA Health Technology Assessment Monograph series, IQR interquartile range, NEJM New England Journal of Medicine, PPI Patient and Public Involvement, SD standard deviation, TSC Trial Steering Committee